Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Turning Point Is Turning Heads


Precision oncology company Turning Point Therapeutics (NASDAQ: TPTX) has gotten off to a hot start since going public in April of 2019. The clinical-stage biotech now sports a market cap approaching $6 billion, up from $1.3 billion at the time of launch. This is in part thanks to a promising investigational drug called repotrectinib. Currently in phase 2 clinical trials, repotrectinib is a tyrosine kinase inhibitor (TKI) taken orally. TKIs can target one or more of three specific drivers of cancer: genes known as ROS1, TRK, and ALK.

Repotrectinib showed promise in recently reported phase 2 data, with patients who took it living longer with fewer side effects than they did when using competing products (Pfizer's (NYSE: PFE) Xalkori and Roche's (OTC: RHHBY) Rozlytrek). In fact, the drug may be best-in-class for ROS1 mutant non-small cell lung cancer, a very specific mutation affecting about 10,000 people per year in the U.S. and EU. All that sounds promising -- but is the sky-high valuation really warranted?

Image Source: Getty Images.

Continue reading


Source Fool.com

Like: 0
Share

Comments